Halozyme Therapeutics | HALO - Debt


Halozyme Therapeutics reported $2.14B in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
Acadia Pharmaceuticals USD 52.19M 2.62M Dec/2025
Agios Pharmaceuticals USD 40.21M 4.31M Dec/2025
Alnylam Pharmaceuticals USD 1.28B 30.06M Dec/2025
Amarin USD 0 0 Mar/2025
Amgen USD 54.6B 17M Dec/2025
Baxter International USD 9.78B 68M Dec/2025
Cara Therapeutics USD 0 0 Mar/2025
Cytokinetics USD 1.29B 4.48M Mar/2026
DBV Technologies USD 8.59M 295K Sep/2025
Eli Lilly USD 42.5B 3.6M Dec/2025
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
Halozyme Therapeutics USD 2.14B 2.01M Mar/2026
Intrexon USD 0 13.82M Jun/2024
Ionis Pharmaceuticals USD 2.34B 9.5M Mar/2026
MannKind USD 367.44M 247.53M Dec/2025
Minerva Neurosciences USD 0 0 Sep/2024
Nektar Therapeutics USD 0 0 Jun/2022
Pfizer USD 63.73B 231M Mar/2026
Rigel Pharmaceuticals USD 59.69M 90K Jun/2024
United Therapeutics USD 200M 100M Mar/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024